Format

Send to

Choose Destination
J Surg Oncol. 2002 May;80(1):27-32; discussion 33.

Ex vivo sentinel lymph node biopsy in colorectal cancer: a feasibility study.

Author information

1
Division of Surgical Oncology and Department of Pathology, Sunnybrook and Women's College Health Sciences Centre, University of Toronto and Toronto-Sunnybrook Regional Cancer Centre.

Abstract

BACKGROUND AND OBJECTIVES:

Sentinel lymph node (SLN) biopsy may improve staging of colorectal cancer. We tested the feasibility of ex vivo SLN dissection.

MATERIALS AND METHODS:

Patients undergoing resection of a primary colorectal cancer were included in this study. SLN identification involved ex vivo injection of 1 cc isosulfan blue dye subserosally in the colon or submucosally in the rectum on a separate field. SLNs were cut at 2 mm intervals. Three hematoxylin and eosin-stained (HE) sections were prepared in addition to a middle level for cytokeratin immunostaining.

RESULTS:

Twenty-six patients with varying tumor location and stage were enrolled and the SLN was identified in 88% (23/26) cases. Three failures occurred in patients with rectal cancer. The average number of SLN harvested was 2.5. The status of the nodal basin was accurately predicted in 91% (21/23) of patients. Two false negative sentinel lymph nodes were harvested in 2 of 3 patients with stage III/IV colorectal cancer. The SLN upstaged 2 patients as a result of HE stained step sections (n = 1) and immunostaining (n = 1).

CONCLUSIONS:

This data suggests that ex vivo SLN biopsy is feasible in colorectal cancer. Although ex vivo SLN biopsy does not alter the lymphatic dissection, it may upstage a subset of patients. The ex vivo technique may be less applicable in rectal cancer and false negative results may occur.

PMID:
11967903
DOI:
10.1002/jso.10091
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center